Eli Lilly retakes innovation crown, while Bristol Myers rates most inventive pharma in annual study

If you gave a pharma a molecule, which one would make the most of it? Eli Lilly, according to IDEA Pharma’s most recent evaluation.

It ranks innovation as a measure of a pharma company’s ability to deliver a “return on invention” over the past five years.

Lilly moved up four spots in 2020, backed by clinical data wins and FDA approvals, as well as strong performance by recently launched drugs, the consultancy reported.